Why Colgate-Palmolive (CL) is a Top Growth Stock for the Long-Term

Zacks' analysis positions Colgate-Palmolive (CL) as a potential growth pick, assigning it a #3 (Hold) Zacks Rank but strong 'B' VGM and Growth Style Scores. The company's strategy emphasizes innovation and expansion into natural product lines, supported by a forecasted 2.2% earnings growth for the current fiscal year. Notably, seven analysts have recently revised their FY2025 earnings estimates upwards, contributing to a Zacks Consensus Estimate of $3.68 per share and a historical average earnings surprise of +3.7%.

Analysis

Colgate-Palmolive (CL) presents a nuanced investment profile, characterized by a neutral Zacks #3 (Hold) rank but strong underlying growth indicators. The company's forward outlook appears positive, supported by a 'B' rating for its Growth Style Score and a forecast for 2.2% year-over-year earnings growth in the current fiscal year. This optimism is further substantiated by recent analyst activity, where seven analysts have revised their fiscal 2025 earnings estimates upward over the last 60 days, lifting the consensus estimate to $3.68 per share. Historically, the company has demonstrated reliability in its performance, posting an average positive earnings surprise of 3.7%. Strategically, CL is positioning for future growth by innovating in core businesses and expanding its 'Naturals' product line to capitalize on the consumer shift towards organic ingredients, reinforcing its standing as a leading consumer goods company.

Key Decisions for Investors

• Investors should look beyond the neutral #3 (Hold) rating and consider the positive forward-looking indicators, such as the 'B' Growth Score and the upward trend in FY2025 earnings estimates.
• Monitor upcoming earnings reports for confirmation of the forecasted 2.2% growth and to assess the materialization of the higher analyst consensus, which would validate the long-term growth thesis.
• For those considering a long position, it is crucial to evaluate the market traction and sales performance of the company's expanded 'Naturals' product range, as its success is a key pillar of the articulated growth strategy.